LMR Partners LLP Makes New Investment in Masimo Co. (NASDAQ:MASI)

LMR Partners LLP acquired a new stake in Masimo Co. (NASDAQ:MASI - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 42,448 shares of the medical equipment provider's stock, valued at approximately $7,017,000. LMR Partners LLP owned about 0.08% of Masimo at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp acquired a new position in Masimo during the fourth quarter worth $27,000. UMB Bank n.a. boosted its stake in Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after buying an additional 123 shares during the last quarter. Trust Co. of Vermont acquired a new position in Masimo during the fourth quarter worth $33,000. Blue Trust Inc. boosted its stake in Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after buying an additional 71 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after buying an additional 64 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Trading Up 0.8%

Shares of Masimo stock traded up $1.23 during trading hours on Friday, hitting $155.62. The company's stock had a trading volume of 537,620 shares, compared to its average volume of 653,640. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $194.88. The firm has a fifty day moving average of $160.06 and a 200-day moving average of $167.33. The stock has a market cap of $8.44 billion, a price-to-earnings ratio of 107.32 and a beta of 1.23. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.12. The firm had revenue of $372.00 million for the quarter, compared to the consensus estimate of $367.79 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company's quarterly revenue was down 24.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 EPS. Research analysts forecast that Masimo Co. will post 4.1 EPS for the current year.

Insider Activity at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares in the company, valued at $4,048,568.28. This represents a 55.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,053 shares of company stock worth $6,998,565. 9.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. BTIG Research set a $193.00 price objective on Masimo and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating and issued a $200.00 price target (down previously from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Wells Fargo & Company decreased their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Finally, Raymond James decreased their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $191.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.